- Home
- QLGN vs PTIX Comparison
QLGN vs PTIX Comparison
Compare QLGN & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- PTIX
- Stock Information
- Founded
- QLGN 1996
- PTIX 1994
- Country
- QLGN United States
- PTIX United States
- Employees
- QLGN N/A
- PTIX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- PTIX Health Care
- Exchange
- QLGN Nasdaq
- PTIX Nasdaq
- Market Cap
- QLGN 2.8M
- PTIX 1.9M
- IPO Year
- QLGN N/A
- PTIX 2016
- Fundamental
- Price
- QLGN $3.77
- PTIX $3.85
- Analyst Decision
- QLGN
- PTIX
- Analyst Count
- QLGN 0
- PTIX 0
- Target Price
- QLGN N/A
- PTIX N/A
- AVG Volume (30 Days)
- QLGN 12.9K
- PTIX 5.6M
- Earning Date
- QLGN 07-01-2025
- PTIX 05-13-2025
- Dividend Yield
- QLGN N/A
- PTIX N/A
- EPS Growth
- QLGN N/A
- PTIX N/A
- EPS
- QLGN N/A
- PTIX N/A
- Revenue
- QLGN N/A
- PTIX N/A
- Revenue This Year
- QLGN N/A
- PTIX N/A
- Revenue Next Year
- QLGN N/A
- PTIX N/A
- P/E Ratio
- QLGN N/A
- PTIX N/A
- Revenue Growth
- QLGN N/A
- PTIX N/A
- 52 Week Low
- QLGN $2.85
- PTIX $2.35
- 52 Week High
- QLGN $29.44
- PTIX $21.00
- Technical
- Relative Strength Index (RSI)
- QLGN 55.45
- PTIX 48.11
- Support Level
- QLGN $3.65
- PTIX $3.71
- Resistance Level
- QLGN $3.90
- PTIX $14.28
- Average True Range (ATR)
- QLGN 0.18
- PTIX 1.41
- MACD
- QLGN -0.01
- PTIX -0.14
- Stochastic Oscillator
- QLGN 40.03
- PTIX 9.15
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.